Category
Basic
Description
Prenatal exposure to environmental xenoestrogens may influence immune system development and contribute to autoimmune disease risk. This study investigates whether Bisphenol-C (BPC), a common substitute for Bisphenol-A (BPA), exhibits similar estrogenic and immunomodulatory effects, and whether it can cross the placental barrier. Using a controlled murine model, dams are assigned to multiple treatment groups receiving estradiol, BPA, or BPC via defined administration methods. Offspring are analyzed at gestational day 17, with collection of amniotic fluid, fetal tissues, and serum. Immune markers, including IL-6 and anti-dsDNA antibodies, are quantified ELISA and flow cytometry, while mass spectrometry is used to confirm BPC presence in amniotic fluid.
Preliminary results demonstrate successful establishment of an F1 generation, though current sample size limits statistical significance. Expected outcomes include elevated inflammatory and autoimmune-associated markers, as well as increased B-cell activity in exposed groups. Detection of BPC in amniotic fluid would support its ability to cross the placental barrier. Future work will expand breeding to increase sample size and refine experimental conditions. This research aims to clarify the potential risks of BPC as a BPA alternative and its role in developmental immune disruption.
Effects of Environmental Xenoestrogens on Immune System Development in Mus Musculus
Basic
Prenatal exposure to environmental xenoestrogens may influence immune system development and contribute to autoimmune disease risk. This study investigates whether Bisphenol-C (BPC), a common substitute for Bisphenol-A (BPA), exhibits similar estrogenic and immunomodulatory effects, and whether it can cross the placental barrier. Using a controlled murine model, dams are assigned to multiple treatment groups receiving estradiol, BPA, or BPC via defined administration methods. Offspring are analyzed at gestational day 17, with collection of amniotic fluid, fetal tissues, and serum. Immune markers, including IL-6 and anti-dsDNA antibodies, are quantified ELISA and flow cytometry, while mass spectrometry is used to confirm BPC presence in amniotic fluid.
Preliminary results demonstrate successful establishment of an F1 generation, though current sample size limits statistical significance. Expected outcomes include elevated inflammatory and autoimmune-associated markers, as well as increased B-cell activity in exposed groups. Detection of BPC in amniotic fluid would support its ability to cross the placental barrier. Future work will expand breeding to increase sample size and refine experimental conditions. This research aims to clarify the potential risks of BPC as a BPA alternative and its role in developmental immune disruption.
